Loading company…
TenNor Therapeutics, based in Suzhou, China, develops antibacterial drugs for digestive tract and other bacterial infections.
Founded in 2013 and based in Suzhou, China, TenNor develops new antibacterial drugs, including TNP-2092IV, TNP-2198 and MDR-TB candidates, for infections such as Helicobacter pylori, drug-resistant tuberculosis and hospital-acquired gram-negative infections. In October 2024 the company raised over CNY 300 million in Series E funding co-led by Zhongshan Venture Capital and AMR Action Fund. The funding will support commercialization of TNP-2198 and late-stage trials of TNP-2092.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in